Author:
Al-Sawaf Othman,Zhang Can,Tandon Maneesh,Sinha Arijit,Fink Anna-Maria,Robrecht Sandra,Samoylova Olga,Liberati Anna M,Pinilla-Ibarz Javier,Opat Stephen,Sivcheva Liliya,Le Dû Katell,Fogliatto Laura M,Niemann Carsten U,Weinkove Robert,Robinson Sue,Kipps Thomas J,Tausch Eugen,Schary William,Ritgen Matthias,Wendtner Clemens-Martin,Kreuzer Karl-Anton,Eichhorst Barbara,Stilgenbauer Stephan,Hallek Michael,Fischer Kirsten
Reference25 articles.
1. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions;Goede;N Engl J Med,2014
2. Goede V, Fischer K, Dyer MJ, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA Annual Meeting; Stockholm; June 14–17, 2018.
3. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia;Shanafelt;N Engl J Med,2019
4. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018
5. Tailored treatment strategies for chronic lymphocytic leukemia in a rapidly changing era;Brander;Am Soc Clin Oncol Educ Book,2019
Cited by
238 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献